Anti-inflammatory activity of thiabendazole and its relation to parasitic disease.
In 6 differnet animal assays in the laboratory, thiabendazole had clear anti-inflammatory effect, though it was less potent than aspirin in all assays. These findings add support to clinical suggestions that the drug may have anti-inflammatory properties in man. Such properties may contribute to the clinical response observed following the use of thiabendazole in cases of trichinosis, cutaneous larva migrans, visceral larva migrans, dracunculosis and scabies. In parasitic infections in which corticosteroids are commonly used in clinical management, notably trichinosis, the fact that thiabendazole does not appear to have immunosuppressive activity may confer an added clinical advantage.
D000818:Animals; D000893:Anti-Inflammatory Agents; D001168:Arthritis / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D002351:Carrageenan; D004285:Dogs; D004320:Dracunculiasis / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D006941:Hyperesthesia / Q000188:drug therapy; D007165:Immunosuppression Therapy; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D007815:Larva Migrans / Q000188:drug therapy; D008297:Male; D051379:Mice; D010272:Parasitic Diseases / Q000188:drug therapy*; D051381:Rats; D013827:Thiabendazole / Q000627:therapeutic use*; D014235:Trichinellosis / Q000188:drug therapy; D014527:Uric Acid; D015002:Yeast, Dried
D000893:Anti-Inflammatory Agents; D014527:Uric Acid; D002351:Carrageenan; D013827:Thiabendazole; D001241:Aspirin